Palbociclib in hormone-receptor-positive advanced breast cancer
Open accessThe DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Growth of hormone-receptor-positive breast cancer is dependent on cyclin-dependent kinases 4 and 6 (CDK4 and CDK6), which promote progression from the G1 phase to the S phase of the cell cycle. We assessed the efficacy of palbociclib (an inhibitor of CDK4 and CDK6) and fulvestrant in advanced breast cancer. METHODS: This phase 3 study involved 521 patients with advanced hormone-receptor-positive, human epidermal growth factor receptor 2-negative breast cancer that had relapsed or progressed during prior endocrine therapy. We randomly assigned patients in a 2:1 ratio to receive palbociclib and fulvestrant or placebo and fulvestrant. Premenopausal or perimenopausal women also received goserelin. The primary end point was investigator-assessed progression-free survival. Secondary end points included overall survival, objective response, rate of clinical benefit, patient-reported outcomes, and safety. A preplanned interim analysis was performed by an independent data and safety monitoring committee after 195 events of disease progression or death had occurred. RESULTS: The median progression-free survival was 9.2 months (95% confidence interval [CI], 7.5 to not estimable) with palbociclib-fulvestrant and 3.8 months (95% CI, 3.5 to 5.5) with placebo-fulvestrant (hazard ratio for disease progression or death, 0.42; 95% CI, 0.32 to 0.56; P<0.001). The most common grade 3 or 4 adverse events in the palbociclib-fulvestrant group were neutropenia (62.0%, vs. 0.6% in the placebo-fulvestrant group), leukopenia (25.2% vs. 0.6%), anemia (2.6% vs. 1.7%), thrombocytopenia (2.3% vs. 0%), and fatigue (2.0% vs. 1.2%). Febrile neutropenia was reported in 0.6% of palbociclib-treated patients and 0.6% of placebo-treated patients. The rate of discontinuation due to adverse events was 2.6% with palbociclib and 1.7% with placebo. CONCLUSIONS: Among patients with hormone-receptor-positive metastatic breast cancer who had progression of disease during prior endocrine therapy, palbociclib combined with fulvestrant resulted in longer progression-free survival than fulvestrant alone. (Funded by Pfizer; PALOMA3 ClinicalTrials.gov number, NCT01942135.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“an interim analysis reported PFS of 9.2 months with palbociclib-fulvestrant and 3.8 months with placebo-fulvestrant (hazard ratio 0.42)”
From Targeting CDK4 and CDK6: From Discovery to Therapy (2016) · cites this paper as [84]
In the citing paper
“This study enrolled pre- and peri-menopausal patients, with benefit of the combination observed across groups.”
From Targeting CDK4 and CDK6: From Discovery to Therapy (2016) · cites this paper as [84]
Citations
Cites
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
Everolimus in Postmenopausal Hormone-Receptor–Positive Advanced Breast Cancer
Baselga, J., Campone, M., Piccart, M., Burris, H. A., Rugo, H. S., Sahmoud, T., Noguchi, S., Gnant, M., Pritchard, K. I., Lebrun, F., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1109653 · Cited by 2,863
Finn, R. S., Crown, J. P., Lang, I., Boer, K., Bondarenko, I. M., Kulyk, S. O., Ettl, J., Patel, R., Pinter, T., Schmidt, M., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(14)71159-3 · Cited by 1,900
Self-citationThe history and future of targeting cyclin-dependent kinases in cancer therapy
Asghar, U., Witkiewicz, A. K., Turner, N. C., & Knudsen, E. S. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4504 · Cited by 1,767
Self-citationFinn, R. S., Dering, J., Conklin, D., Kalous, O., Cohen, D. J., Desai, A. J., Ginther, C., Atefi, M., Chen, I., Fowst, C., et al. (2009) · Breast Cancer Research · doi:10.1186/bcr2419 · Cited by 1,398
Cyclin D as a therapeutic target in cancer
Musgrove, E. A., Caldon, C. E., Barraclough, J., Stone, A., & Sutherland, R. L. (2011) · Nature Reviews Cancer · doi:10.1038/nrc3090 · Cited by 1,370
ESR1 ligand-binding domain mutations in hormone-resistant breast cancer
Toy, W., Shen, Y., Won, H., Green, B., Sakr, R. A., Will, M., Li, Z., Gala, K., Fanning, S., King, T. A., et al. (2013) · Nature Genetics · doi:10.1038/ng.2822 · Cited by 1,248
Activating ESR1 mutations in hormone-resistant metastatic breast cancer
Robinson, D. R., Wu, Y.-M., Vats, P., Su, F., Lonigro, R. J., Cao, X., Kalyana-Sundaram, S., Wang, R., Ning, Y., Hodges, L., et al. (2013) · Nature Genetics · doi:10.1038/ng.2823 · Cited by 1,145
Adjuvant Ovarian Suppression in Premenopausal Breast Cancer
Francis, P. A., Regan, M. M., Fleming, G. F., Láng, I., Ciruelos, E., Bellet, M., Bonnefoi, H. R., Climent, M. A., Da Prada, G. A., Burstein, H. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1412379 · Cited by 726
Cited by
Items 501–600 of 1,000
Potential biomarkers of CDK4/6 inhibitors in hormone receptor-positive advanced breast cancer
Fang, H., Huang, D., Yang, F., & Guan, X. (2017) · Breast Cancer Research and Treatment · doi:10.1007/s10549-017-4612-y · Cited by 36
Brisard, D., Eckerdt, F., Marsh, L. A., Blyth, G. T., Jain, S., Cristofanilli, M., Horiuchi, D., & Platanias, L. C. (2018) · Oncotarget · doi:10.18632/oncotarget.26468 · Cited by 37
Self-citationShah, A. N., Metzger, O., Bartlett, C. H., Liu, Y., Huang, X., & Cristofanilli, M. (2020) · The Oncologist · doi:10.1634/theoncologist.2019-0729 · Cited by 39
Self-citationKi67 and PR in Patients Treated with CDK4/6 Inhibitors: A Real-World Experience
Palleschi, M., Maltoni, R., Ravaioli, S., Vagheggini, A., Mannozzi, F., Fanini, F., Pirini, F., Tumedei, M. M., Barzotti, E., Cecconetto, L., et al. (2020) · Diagnostics · doi:10.3390/diagnostics10080573 · Cited by 37
Harnessing the immunotherapeutic potential of CDK4/6 inhibitors in melanoma: is timing everything?
Lelliott, E. J., Sheppard, K. E., & McArthur, G. A. (2022) · npj Precision Oncology · doi:10.1038/s41698-022-00273-9 · Cited by 39
Qayoom, H., Mehraj, U., Sofi, S., Aisha, S., Almilaibary, A., Alkhanani, M., & Mir, M. A. (2022) · Medical Oncology · doi:10.1007/s12032-022-01779-9 · Cited by 35
Pascual, J., Gil‐Gil, M., Proszek, P., Zielinski, C. C., Reay, A., Ruíz-Borrego, M., Cutts, R. J., Ciruelos, E., Feber, A., Muñoz-Mateu, M., et al. (2023) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-23-0956 · Cited by 38
Self-citationXie, D., Ren, Z., Fan, J., & Gao, Q. (2016) · PubMed Central · Cited by 38
Manso, L., Mouron, S. A., Tress, M. L., Goméz-López, G., Morente, M. M., Ciruelos, E., Rubio-Camarillo, M., Rodríguez‐Peralto, J. L., Pujana, M. Á., Pisano, D. G., et al. (2016) · PLoS ONE · doi:10.1371/journal.pone.0155840 · Cited by 37
Blockade of CDK7 Reverses Endocrine Therapy Resistance in Breast Cancer
Attia, Y. M., Shouman, S. A., Salama, S. A., Ivan, C., Elsayed, A. M., Amero, P., Rodriguez‐Aguayo, C., & Lopez‐Berestein, G. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21082974 · Cited by 36
“Currently many CDK inhibitors are in clinical use, including the CDK4/6 inhibitor palbociclib, which showed a synergistic effect with endocrine therapy in patients with ERα+ breast cancer [30,31].”
BackgroundBrandão, M., Maurer, C., Ziegelmann, P. K., Ponde, N. F., Ferreira, A. R., Martel, S., Piccart, M. J., de Azambuja, E., Debiasi, M., & Lambertini, M. (2020) · ESMO Open · doi:10.1136/esmoopen-2020-000842 · Cited by 34
New Therapeutic Strategies for Adult Acute Myeloid Leukemia
Ishii, H., & Yano, S. (2022) · Cancers · doi:10.3390/cancers14112806 · Cited by 37
JNKs function as CDK4-activating kinases by phosphorylating CDK4 and p21
Colleoni, B., Paternot, S., Pita, J. M. G., Bisteau, X., Coulonval, K., Davis, R. J., Raspé, E., & Roger, P. P. (2017) · Oncogene · doi:10.1038/onc.2017.7 · Cited by 35
Translational Genomics: Practical Applications of the Genomic Revolution in Breast Cancer
Yates, L. R., & Desmedt, C. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-2548 · Cited by 38
Meta-analysis of selected toxicity endpoints of CDK4/6 inhibitors: Palbociclib and ribociclib
Costa, R., da Costa, R. B., Talamantes, S., Helenowski, I., Peterson, J., Kaplan, J. B., Carneiro, B. A., Giles, F. J., & Gradishar, W. J. (2017) · The Breast · doi:10.1016/j.breast.2017.05.016 · Cited by 37
du Rusquec, P., Palpacuer, C., Campion, L., Patsouris, A., Augereau, P., Gourmelon, C., Robert, M., Dumas, L. E., Folliard, C., Campone, M., et al. (2017) · Breast Cancer Research and Treatment · doi:10.1007/s10549-017-4623-8 · Cited by 36
Galve-Calvo, E., González-Haba, E., Gostkorzewicz, J., Martínez, I. V., & Pérez-Mitru, A. (2018) · ClinicoEconomics and Outcomes Research · doi:10.2147/ceor.s178934 · Cited by 33
Ye, H., & Shaw, I. C. (2019) · Food and Chemical Toxicology · doi:10.1016/j.fct.2019.04.008 · Cited by 36
Sante, G. D., Pagé, J., Jiao, X., Nawab, O., Cristofanilli, M., Skordalakes, E., & Pestell, R. G. (2019) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2019.1615889 · Cited by 34
Self-citationManagement of ER positive metastatic breast cancer
McAndrew, N. P., & Finn, R. S. (2020) · Seminars in Oncology · doi:10.1053/j.seminoncol.2020.07.005 · Cited by 36
Rugo, H. S., Cristofanilli, M., Loibl, S., Harbeck, N., DeMichele, A. M., Iwata, H., Park, Y. H., Brufsky, A., Theall, K. P., Huang, X., et al. (2021) · The Oncologist · doi:10.1002/onco.13833 · Cited by 34
Self-citationVenous and arterial thrombosis associated with abemaciclib therapy for metastatic breast cancer
Watson, N. W., Wander, S. A., Shatzel, J. J., & Al-Samkari, H. T. (2022) · Cancer · doi:10.1002/cncr.34367 · Cited by 34
Sibaud, V., & Sollena, P. (2023) · Annales de Dermatologie et de Vénéréologie · doi:10.1016/j.annder.2022.11.013 · Cited by 33
Genomically personalized therapy in head and neck cancer
Aung, K. L., & Siu, L. L. (2016) · Cancers of the Head & Neck · doi:10.1186/s41199-016-0004-y · Cited by 38
O'Sullivan, C. C. (2015) · International Journal of Cancer and Clinical Research · doi:10.23937/2378-3419/2/4/1029 · Cited by 35
Ferrero, J.-M., Bessard, A. C. H., Capitain, O., Lortholary, A. H., Salles, B., Follana, P., Hervé, R., Deblock, M., Dauba, J., Atlassi, M., et al. (2016) · Cancer · doi:10.1002/cncr.30170 · Cited by 33
High-Order Drug Combinations Are Required to Effectively Kill Colorectal Cancer Cells
Horn, T. L., Ferretti, S., Ebel, N., Tam, A., Ho, S. B., Harbinski, F., Farsidjani, A., Zubrowski, M. J., Sellers, W. R., Schlegel, R., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-3425 · Cited by 36
The Power Behind the Throne: Senescence and the Hallmarks of Cancer
Hoare, M., & Narita, M. (2017) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-030617-050352 · Cited by 33
CDK4/6 blockade in breast cancer: current experience and future perspectives
Zardavas, D., Ponde, N. F., & Tryfonidis, K. (2017) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2017.1389896 · Cited by 35
PAK4 regulates stemness and progression in endocrine resistant ER-positive metastatic breast cancer
Santiago-Gómez, A., Kedward, T., Simões, B. M., Dragoni, I., NicAmhlaoibh, R., Trivier, E., Sabin, V., Gee, J. M. W., Sims, A. H., Howell, S. J., et al. (2019) · Cancer Letters · doi:10.1016/j.canlet.2019.05.014 · Cited by 33
Denkert, C., Rachakonda, S., Karn, T., Weber, K. E., Martin, M., Marmé, F., Untch, M., Bonnefoi, H. R., Kim, S., Seiler, S., et al. (2025) · Cancer Cell · doi:10.1016/j.ccell.2025.01.002 · Cited by 34
Self-citationPrecision medicine for advanced prostate cancer
Mullane, S. A., & Allen, E. M. V. (2016) · Current Opinion in Urology · doi:10.1097/mou.0000000000000278 · Cited by 35
Cell Cycle Regulation in Treatment of Breast Cancer
Cai, Z., & Liu, Q. (2017) · Advances in experimental medicine and biology · doi:10.1007/978-981-10-6020-5_12 · Cited by 37
Maculaitis, M. C., Liu, X., Will, O., Hanson, M., McRoy, L., Berk, A. R., & Crastnopol, M. (2020) · Patient Preference and Adherence · doi:10.2147/ppa.s254934 · Cited by 32
Brighi, N., Conteduca, V., Lolli, C., Gurioli, G., Schepisi, G., Palleschi, M., Mariotti, M., Casadei, C., & Giorgi, U. D. (2020) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2020.103199 · Cited by 33
Thill, M., Jackisch, C., Janni, W., Müller, V., Albert, U., Bauerfeind, I., Blohmer, J., Budach, W., Dall, P., Diel, I., et al. (2019) · Breast Care · doi:10.1159/000500999 · Cited by 36
Self-citationSETDB1 Modulates Degradation of Phosphorylated RB and Anticancer Efficacy of CDK4/6 Inhibitors
Huang, Z., Li, X., Tang, B., Li, H., Zhang, J., Sun, R., Ma, J., Pan, Y., Yan, B., Zhou, Y., et al. (2023) · Cancer Research · doi:10.1158/0008-5472.can-22-0264 · Cited by 32
Shan, C., Yan, L., Wang, K., & Li, P. (2023) · International Journal of Biological Sciences · doi:10.7150/ijbs.88500 · Cited by 35
Over-treatment in metastatic breast cancer
Senkus, E., & Łacko, A. (2016) · The Breast · doi:10.1016/j.breast.2016.06.024 · Cited by 32
Jhaveri, K. L., Bellet, M., Turner, N. C., Loi, S., Bardia, A., Boni, V., Sohn, J., Neilan, T. G., Villanueva-Vázquez, R., Kabos, P., et al. (2023) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-23-1796 · Cited by 32
Self-citationSignaling pathway dysregulation in breast cancer
Ryspayeva, D., Seyhan, A. A., MacDonald, W., Purcell, C., Roady, T. J., Ghandali, M., Verovkina, N., El‐Deiry, W. S., Taylor, M. S., & Graff, S. L. (2025) · Oncotarget · doi:10.18632/oncotarget.28701 · Cited by 33
Deng, Y., Ma, G., Li, W., Wang, T. I., Zhao, Y., & Wu, Q. (2018) · Clinical Breast Cancer · doi:10.1016/j.clbc.2018.04.017 · Cited by 37
Ratoša, I., Oražem, M., Scoccimarro, E., Steinacher, M., Dominici, L., Aquilano, M., Cerbai, C., Desideri, I., Ribnikar, D., Marinko, T., et al. (2020) · Clinical Breast Cancer · doi:10.1016/j.clbc.2020.05.013 · Cited by 31
Finn, R. S., Cristofanilli, M., Ettl, J., Gelmon, K. A., Colleoni, M. A., Giorgetti, C., Gauthier, E. R., Liu, Y., Lu, D. R., Zhang, Z., et al. (2020) · Breast Cancer Research and Treatment · doi:10.1007/s10549-020-05782-4 · Cited by 33
Self-citationReal-World Palbociclib Use in HR+/HER2− Advanced Breast Cancer in Canada: The IRIS Study
Mycock, K., Zhan, L., Taylor‐Stokes, G., Milligan, G., & Mitra, D. (2021) · Current Oncology · doi:10.3390/curroncol28010066 · Cited by 33
Beachler, D. C., de Luise, C., Jamal‐Allial, A., Yin, R., Taylor, D. H., Suzuki, A., Lewis, J. H., Freston, J. W., & Lanes, S. (2021) · BMC Cancer · doi:10.1186/s12885-021-07790-z · Cited by 34
Robertson, J. F. R., Leo, A. D., Johnston, S. R. D., Chia, S., Bliss, J. M., Paridaens, R., Lichfield, J., Bradbury, I., & Campbell, C. (2021) · npj Breast Cancer · doi:10.1038/s41523-021-00222-y · Cited by 33
Iwata, H., Umeyama, Y., Liu, Y., Zhang, Z., Schnell, P., Mori, Y., Fletcher, O., Marshall, J.-C. A., Johnson, J. G., Wood, L. S., et al. (2021) · The Oncologist · doi:10.1002/onco.13811 · Cited by 35
“Both studies were conducted according to the principles of Good Clinical Practice and the Declaration of Helsinki [4, 5].”
MethodSelf-citationKahán, Z., Gil‐Gil, M., Ruíz‐Borrego, M., Carrasco, E., Ciruelos, E., Muñoz-Mateu, M., Bermejo, B., Vila, M. M., Antón, A., Casas, M., et al. (2021) · European Journal of Cancer · doi:10.1016/j.ejca.2021.07.004 · Cited by 33
ARID1A Mutation in Metastatic Breast Cancer: A Potential Therapeutic Target
Cheng, X., Zhao, J., Dong, F., & Cao, X. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.759577 · Cited by 35
Engler, T., Fasching, P. A., Lüftner, D., Hartkopf, A. D., Müller, V., Kolberg, H., Hadji, P., Tesch, H., Häberle, L., Ettl, J., et al. (2022) · Geburtshilfe und Frauenheilkunde · doi:10.1055/a-1880-0087 · Cited by 31
Ladd, B., Mazzola, A. M., Bihani, T., Lai, Z., Bradford, J. R., Collins, M. P., Barry, E., Goeppert, A. U., Weir, H. M., Hearne, K., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.10852 · Cited by 32
Teh, J. L. F., Purwin, T. J., Greenawalt, E. J., Chervoneva, I., Goldberg, A. F., Davies, M. A., & Aplin, A. E. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-3384 · Cited by 36
Haddad, T. C., D’Assoro, A. B., Suman, V. J., Opyrchal, M., Peethambaram, P. P., Liu, M., Goetz, M. P., & Ingle, J. N. (2017) · Breast Cancer Research and Treatment · doi:10.1007/s10549-017-4616-7 · Cited by 31
Preclinical and clinical development of palbociclib and future perspectives
de Dueñas, E. M., Gavilá-Gregori, J., Olmos-Antón, S., Santaballa, A., Lluch-Hernández, A., Domínguez, E. E., Rivero-Silva, M., & Llombart‐Cussac, A. (2018) · Clinical & Translational Oncology · doi:10.1007/s12094-018-1850-3 · Cited by 36
Li, J., Wang, Z., & Shao, Z. (2019) · Cancer Medicine · doi:10.1002/cam4.2095 · Cited by 32
CDK4 and CDK6 Inhibition in Breast Cancer — A New Standard
Wolff, A. C. (2016) · New England Journal of Medicine · doi:10.1056/nejme1611926 · Cited by 34
Real-world effectiveness of CDK 4/6 inhibitors in estrogen-positive metastatic breast cancer
Gehrchen, M. L., Berg, T., Garly, R., Jensen, M., Eßer-Naumann, S., Rønlev, J. D., Nielsen, H. M., Knoop, A. S., & Kümler, I. (2024) · BJC Reports · doi:10.1038/s44276-024-00070-w · Cited by 32
SEOM clinical guidelines in metastatic breast cancer 2015
Gavilá, J., López‐Tarruella, S., Saura, C., Muñoz-Mateu, M., Oliveira, M., de la Cruz‐Merino, L., Morales, S. M., Álvarez, I., Virizuela, J. A., & Martín, M. (2015) · Clinical & Translational Oncology · doi:10.1007/s12094-015-1476-7 · Cited by 34
Turner‐Bowker, D. M., Hao, Y., Foley, C., Galipeau, N., Mazar, I., Krohe, M., GLOBE, D. R., & Shields, A. L. (2016) · Current Medical Research and Opinion · doi:10.1080/03007995.2016.1205005 · Cited by 33
Knudsen, E. S., & Witkiewicz, A. K. (2016) · Oncotarget · doi:10.18632/oncotarget.11588 · Cited by 32
Massarweh, S. A., & Choi, G. L. (2016) · Current Problems in Cancer · doi:10.1016/j.currproblcancer.2016.09.003 · Cited by 35
Targeting androgen-independent pathways: new chances for patients with prostate cancer?
Cattrini, C., Zanardi, E., Vallome, G., Cavo, A., Cerbone, L., Meglio, A. D., Fabbroni, C., Latocca, M. M., Rizzo, F., Messina, C. G. M., et al. (2017) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2017.08.009 · Cited by 34
Seidman, A. D., Bordeleau, L. J., Fehrenbacher, L., Barlow, W. E., Perlmutter, J., Rubinstein, L., Wedam, S. B., Hershman, D. L., Hayes, J. F., Butler, L. P., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.18.00242 · Cited by 30
CDK4-6 inhibitors in breast cancer: current status and future development
Choo, J. R.-E., & Lee, S. C. (2018) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2018.1541347 · Cited by 32
The Future of ER+/HER2− Metastatic Breast Cancer Therapy: Beyond PI3K Inhibitors
Stravodimou, A., & Voutsadakis, I. A. (2020) · Anticancer Research · doi:10.21873/anticanres.14486 · Cited by 33
Davidson, C. D., Gillis, N. E., & Carr, F. E. (2021) · Cancers · doi:10.3390/cancers13174254 · Cited by 35
Chen, R., Chen, Y., Xiong, P., Zheleva, D. I., Blake, D., Keating, M. J., Wierda, W. G., & Plunkett, W. K. (2022) · Leukemia · doi:10.1038/s41375-022-01553-w · Cited by 31
Buller, W., Pallan, L., Chu, T., & Khoja, L. (2023) · Journal of Oncology Pharmacy Practice · doi:10.1177/10781552231163121 · Cited by 33
Mehata, A. K., Singh, V., Vikas, V., Singh, N. K., Mandal, A., Dash, D., Koch, B., & Muthu, M. S. (2023) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.3c03184 · Cited by 31
Li, N., Du, E. X., Chu, L.-H., Peeples, M., Xie, J., Barghout, V. E., & Tang, D. H. (2017) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2017.1351947 · Cited by 30
Prada, E. T. A., & Auernhammer, C. J. (2017) · Endocrine Connections · doi:10.1530/ec-17-0286 · Cited by 33
Hylebos, M., Camp, G. V., Vandeweyer, G., Fransén, E., Beyens, M., Cornelissen, R., Suls, A., Pauwels, P., van Meerbeeck, J. P., & de Beeck, K. O. (2017) · Oncotarget · doi:10.18632/oncotarget.22817 · Cited by 30
Recurrent CCND3 mutations in MLL-rearranged acute myeloid leukemia
Matsuo, H., Yoshida, K., Fukumura, K., Nakatani, K., Noguchi, Y., Takasaki, S., Noura, M., Shiozawa, Y., Shiraishi, Y., Chiba, K., et al. (2018) · Blood Advances · doi:10.1182/bloodadvances.2018019398 · Cited by 32
Iorfida, M., Mazza, M., & Munzone, E. (2020) · Breast Cancer Targets and Therapy · doi:10.2147/bctt.s196240 · Cited by 33
RON signalling promotes therapeutic resistance in ESR1 mutant breast cancer
Dustin, D. J., Gu, G., Beyer, A. R., Herzog, S. K., Edwards, D. G., Lin, H., Gonzalez, T. L., Grimm, S. L., Coarfa, C., Chan, D. W., et al. (2020) · British Journal of Cancer · doi:10.1038/s41416-020-01174-z · Cited by 31
Catlin, N. R., Bowman, C., Engel, S., Sacaan, A. I., Thibault, S., Lewis, E. M., & Cappon, G. D. (2019) · Reproductive Toxicology · doi:10.1016/j.reprotox.2019.07.016 · Cited by 30
Strategic Combinations to Prevent and Overcome Resistance to Targeted Therapies in Oncology
Gümüşay, Ö., Vitiello, P. P., Wabl, C. A., Corcoran, R. B., Bardelli, A., & Rugo, H. S. (2020) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_280845 · Cited by 33
Tan, H., Cheung, P., Louie, A. V., Myrehaug, S. D., Niglas, M., Atenafu, E. G., Chu, W., Chung, H. T.-K., Poon, I., Sahgal, A., et al. (2021) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2021.06.012 · Cited by 29
Therapeutic potential of CDK4/6 inhibitors in renal cell carcinoma
Sager, R., Backe, S. J., Ahanin, E. F., Smith, G., Nsouli, I. S., Woodford, M. R., Bratslavsky, G., Bourboulia, D., & Mollapour, M. (2022) · Nature Reviews Urology · doi:10.1038/s41585-022-00571-8 · Cited by 29
Hajjo, R., Sabbah, D. A., Abusara, O. H., Kharmah, R., & Bardaweel, S. K. (2023) · Viruses · doi:10.3390/v15020568 · Cited by 29
Treatment of De-Differentiated Liposarcoma in the Era of Immunotherapy
Zhou, M. Y., Bui, N. Q., Charville, G. W., Ganjoo, K. N., & Pan, M. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24119571 · Cited by 31
“This trial was extended with an expansion cohort that enrolled an additional 30 patients (90% were DDLPS), and the dosing was changed to 125 mg for 21 days in a 28-day cycle which is the standard dosing for patients with advanced breast cancer [49,66,77].”
MethodZeverijn, L. J., Looze, E. J., Thavaneswaran, S., Henegouwen, J. M. V. B., Simes, R. J., Hoes, L. R., Sjoquist, K. M., van der Wijngaart, H., Sebastian, L. T., Geurts, B. S., et al. (2023) · International Journal of Cancer · doi:10.1002/ijc.34649 · Cited by 32
Kelly, P., Ma, Z., Baidas, S. M., Moroose, R., Shah, N. C., Dagan, R., Mamounas, E. P., & Rineer, J. M. (2017) · International Journal of Breast Cancer · doi:10.1155/2017/1367159 · Cited by 29
Differences of cyclin-dependent kinase 4/6 inhibitor, palbociclib and abemaciclib, in breast cancer
Tamura, K. (2019) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyz151 · Cited by 31
Basal-shift transformation leads to EGFR therapy-resistance in human lung adenocarcinoma
Shinozaki, T., Togasaki, K., Hamamoto, J., Mitsuishi, A., Fukushima, T., Sugihara, K., Ebisudani, T., Okada, M., Saito, A., Shigematsu, L., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-59623-3 · Cited by 33
Taralli, S., Lorusso, M., Scolozzi, V., Masiello, V., Marazzi, F., & Calcagni, M. L. (2018) · Annals of Nuclear Medicine · doi:10.1007/s12149-018-01323-8 · Cited by 28
Framarino‐dei‐Malatesta, M., Chiarito, A., Bianciardi, F., Fiorelli, M., Ligato, A., Naso, G., & Pecorella, I. (2019) · BMC Cancer · doi:10.1186/s12885-018-5253-1 · Cited by 28
Liao, H., Huang, W., Pei, W., & Li, H. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.587671 · Cited by 30
Fusion‐associated carcinomas of the breast: Diagnostic, prognostic, and therapeutic significance
Loo, S. K., Yates, M. E., Yang, S., Oesterreich, S., Lee, A. V., & Wang, X. (2022) · Genes Chromosomes and Cancer · doi:10.1002/gcc.23029 · Cited by 28
Potent molecular-targeted therapies for advanced esophageal squamous cell carcinoma
Ooki, A., Osumi, H., Chìn, K., Watanabe, M., & Yamaguchi, K. (2023) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359221138377 · Cited by 31
Clinical outcomes based on multigene profiling in metastatic breast cancer patients
Basho, R. K., Gagliato, D. D. M., Ueno, N. T., Wathoo, C., Chen, H., Shariati, M., Wei, C., Álvarez, R. H., Moulder, S. L., Şahin, A. A., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.12987 · Cited by 28
Pharmacokinetic drug evaluation of palbociclib for the treatment of breast cancer
Luca, A. D., Maiello, M. R., D’Alessio, A., Frezzetti, D., Gallo, M., Carotenuto, M., & Normanno, N. (2018) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2018.1514720 · Cited by 29
Let This Be Our New Year’s Pledge
Chabner, B. A., & Murphy, M. J. (2017) · The Oncologist · doi:10.1634/theoncologist.2017-0001 · Cited by 28
Hurvitz, S. A., Layman, R. M., Curigliano, G., André, F., Cristofanilli, M., Kim, S., Rodriguez, J. L. M., Nadal, J. C., Kim, G. M., Lo, L. L., et al. (2026) · Journal of Clinical Oncology · doi:10.1200/jco-25-02643 · Cited by 28
Self-citationCurrent Strategies of Endocrine Therapy in Elderly Patients with Breast Cancer
Lee, S., & Seo, J. H. (2018) · BioMed Research International · doi:10.1155/2018/6074808 · Cited by 29
Novel Therapeutic Targets in Cutaneous Squamous Cell Carcinoma
Yanagi, T., Kitamura, S., & Hata, H. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00079 · Cited by 27
Chen, R., Guo, S., Yang, C., Sun, L., Zong, B., Li, K., Liu, L., Tu, G., Liu, M., & Liu, S. (2020) · International Journal of Oncology · doi:10.3892/ijo.2020.4987 · Cited by 28
Major clinical research advances in gynecologic cancer in 2015
Suh, D. H., Kim, M., Kim, H. J., Lee, K.-H., & Kim, J. (2016) · Journal of Gynecologic Oncology · doi:10.3802/jgo.2016.27.e53 · Cited by 27
Eziokwu, A. S., Varella, L., Kruse, M. L., Jia, X., Moore, H. C. F., Budd, G. T., Abraham, J., & Montero, A. J. (2020) · Clinical Breast Cancer · doi:10.1016/j.clbc.2020.09.010 · Cited by 28
Metadata
- Authors
- Turner, N. C., Ro, J., André, F., Loi, S., Verma, S., Iwata, H., Harbeck, N., Loibl, S., Huang Bartlett, C., Zhang, K., Giorgetti, C., Randolph, S., Koehler, M., & Cristofanilli, M.
- Affiliations
- Sunnybrook Health Science Centre (CA)
- National Cancer Center (KR)
- Institut Gustave Roussy (FR)
- The University of Melbourne (AU)
- Aichi Cancer Center Hospital (JP)
- Ludwig-Maximilians-Universität München (DE)
- German Breast Group (DE)
- Pfizer (United States) (US)
- Thomas Jefferson University (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2015-07-16
- Volume
- 373
- Issue
- 3
- Pages
- 209-219
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W1464936406
- Cited by
- 1,590
- References
- 26
- Citations by year
- 2026: 67 · 2025: 142 · 2024: 117 · 2023: 109 · 2022: 127 · 2021: 142 · 2020: 172 · 2019: 123 · 2018: 169 · 2017: 193 · 2016: 179 · 2015: 49
- FWCI
- 154.46
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Research Publications (Maastricht University) (publishedVersion, other-oa)
- The Medicine Forum (submittedVersion)
- Figshare (submittedVersion, cc-by)
- Research Publications (Maastricht University) (submittedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Advanced Breast Cancer Therapies
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
- Health Sciences › Medicine › Oncology › PARP inhibition in cancer therapy
- Keywords
- palbociclib, hormone receptor-positive breast cancer, HER2-negative breast cancer, CDK4/6 inhibitors, fulvestrant, progression-free survival, endocrine therapy resistance, neutropenia, febrile neutropenia, goserelin, metastatic breast cancer, G1/S transition, adverse events, overall survival
- MeSH terms
- Fulvestrant, Adult, Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols, Breast Neoplasms, Double-Blind Method, Estradiol, Female, Humans, Middle Aged, Piperazines, Pyridines, Receptors, Estrogen, Receptors, Progesterone, Biomarkers, Disease-Free Survival, Erb-b2 Receptor Tyrosine Kinases, Protein Kinase Inhibitors, Cyclin-Dependent Kinase 4, Cyclin-Dependent Kinase 6
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.